- XV Eurasian Hematology-Oncology Congress - EHOC 2024
- XIV Eurasian Hematology-Oncology Congress - EHOC 2023
- 8th Eurasian Hematology Oncology Summit
- XIth Eurasian Hematology-Oncology Congress - EHOC 2020
- 7th Eurasian Hematology Oncology Summit
- Xth Eurasian Hematology-Oncology Congress
- Events
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time -0:00
1x
- 0.5x
- 0.75x
- 1x, selected
- 1.25x
- 1.5x
- 1.75x
- 2x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
10 seconds
Playback speed
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Novel Agents in the Treatment of R/R CLL
45 views
October 9, 2024
Chapters
Decade of CLL Target Therapy & Recent Approvals
00:00
Treatment Sequencing Scenarios in CLL
01:38
Transition from Ibrutinib to Second-Gen BTK Inhibitors
03:54
Pirtobrutinib Approval & Resistance Challenges
05:51
CAR-T Liso-cel Approval & PFS Analysis
10:21
Emerging CLL Therapies & BTK Degraders
12:17
Comments 0
Login to view comments.
Click here to Login
Leukemia